share_log

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Down to $19.57

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Down to $19.57

CRinetics製藥公司(納斯達克代碼：CRNX)股價下跌至19.57美元
Financial News Live ·  2022/09/22 14:41

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Rating) shares gapped down prior to trading on Thursday . The stock had previously closed at $19.57, but opened at $18.89. Crinetics Pharmaceuticals shares last traded at $18.89, with a volume of 302 shares traded.

Crinetics製藥公司(納斯達克代碼：CRNX-GET評級)的股價在週四交易前大幅下跌。該股此前收盤報19.57美元，開盤報18.89美元。Crinetics PharmPharmticals的股票尾盤報18.89美元，成交量為302股。

Analyst Upgrades and Downgrades

分析師升級和下調評級

Separately, SVB Leerink upped their target price on shares of Crinetics Pharmaceuticals from $36.00 to $39.00 and gave the stock an "outperform" rating in a report on Thursday, May 26th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $39.67.

另外，SVB Leerink在5月26日(星期四)的一份報告中將Crinetics PharmPharmticals的目標價從36.00美元上調至39.00美元，並給予該股“跑贏大盤”的評級。根據MarketBeat的數據，五位分析師對該股的評級為買入，共識評級為買入，平均目標價為39.67美元。

Get
到達
Crinetics Pharmaceuticals
Crinetics製藥公司
alerts:
警報：

Crinetics Pharmaceuticals Price Performance

Crinetics藥品價格表現

The stock has a market capitalization of $1.02 billion, a PE ratio of -6.63 and a beta of 1.20. The stock's 50 day simple moving average is $20.57 and its two-hundred day simple moving average is $20.13.

該股市值10.2億美元，市盈率為-6.63，貝塔係數為1.20。該股的50日簡單移動均線切入位為20.57美元，200日簡單移動均線切入位為20.13美元。

Insider Buying and Selling at Crinetics Pharmaceuticals

Crinetics PharmPharmticals的內幕買賣

In other news, insider Stephen F. Betz sold 4,168 shares of the business's stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $21.01, for a total value of $87,569.68. Following the sale, the insider now owns 100,598 shares of the company's stock, valued at $2,113,563.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through
在其他新聞方面，內部人士斯蒂芬·F·貝茨在9月15日星期四的一次交易中出售了4168股該公司的股票。這些股票的平均價格為21.01美元，總價值為87,569.68美元。出售後，這位內部人士現在擁有100,598股該公司股票，價值2,113,563.98美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過
the SEC website
美國證券交易委員會網站
. In other news, Director Matthew K. Fust sold 5,700 shares of the business's stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $20.96, for a total value of $119,472.00. Following the sale, the director now owns 12,536 shares of the company's stock, valued at $262,754.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through
。在其他新聞方面，董事馬修·K·福斯特在7月13日(星期三)的一筆交易中出售了5,700股該公司股票。這些股票的平均價格為20.96美元，總價值為119,472.00美元。出售後，董事現在擁有12536股該公司的股票，價值262,754.56美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過
the SEC website
美國證券交易委員會網站
. Also, insider Stephen F. Betz sold 4,168 shares of the business's stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $21.01, for a total transaction of $87,569.68. Following the transaction, the insider now directly owns 100,598 shares of the company's stock, valued at approximately $2,113,563.98. The disclosure for this sale can be found
。此外，內部人士斯蒂芬·F·貝茨在9月15日星期四的一次交易中出售了4168股該公司的股票。這些股票以21.01美元的平均價格出售，總成交金額為87,569.68美元。交易完成後，這位內部人士現在直接持有該公司100,598股股票，價值約2,113,563.98美元。關於這次銷售的披露可以找到
here
這裏
. Insiders have sold a total of 12,062 shares of company stock worth $252,770 over the last three months. 5.90% of the stock is currently owned by insiders.
。過去三個月，內部人士總共出售了12,062股公司股票，價值252,770美元。該公司5.90%的股份目前由內部人士持有。

Hedge Funds Weigh In On Crinetics Pharmaceuticals

對衝基金買入Crinetics製藥公司

Several hedge funds have recently bought and sold shares of the company. Federated Hermes Inc. grew its stake in Crinetics Pharmaceuticals by 2.6% during the first quarter. Federated Hermes Inc. now owns 25,482 shares of the company's stock valued at $559,000 after acquiring an additional 646 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in Crinetics Pharmaceuticals by 9.7% during the first quarter. DekaBank Deutsche Girozentrale now owns 11,300 shares of the company's stock valued at $215,000 after acquiring an additional 1,000 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Crinetics Pharmaceuticals by 17.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,493 shares of the company's stock valued at $164,000 after acquiring an additional 1,110 shares in the last quarter. American International Group Inc. grew its stake in Crinetics Pharmaceuticals by 7.6% in the 2nd quarter. American International Group Inc. now owns 24,630 shares of the company's stock worth $459,000 after buying an additional 1,749 shares in the last quarter. Finally, Group One Trading L.P. increased its holdings in shares of Crinetics Pharmaceuticals by 31.6% in the 1st quarter. Group One Trading L.P. now owns 7,318 shares of the company's stock worth $161,000 after buying an additional 1,759 shares during the last quarter. Hedge funds and other institutional investors own 94.42% of the company's stock.

幾家對衝基金最近買賣了該公司的股票。今年第一季度，聯合愛馬仕公司在Crinetics PharmPharmticals的持股增加了2.6%。聯合愛馬仕公司目前持有25,482股該公司股票，價值55.9萬美元，該公司在上個季度增持了646股。第一季度，德意志銀行在Crinetics PharmPharmticals的持股增加了9.7%。在上個季度增持了1,000股德意志銀行股票後，德意志銀行現在持有11,300股該公司股票，價值21.5萬美元。Zurcher Kantonalbank蘇黎世廣東銀行第一季度增持Crinetics PharmPharmticals股份17.4%。Zurcher Kantonalbank蘇黎世廣東銀行在上個季度增持了1110股後，現在擁有7493股該公司股票，價值16.4萬美元。美國國際集團(American International Group Inc.)在第二季度增持了Crinetics PharmPharmticals 7.6%的股份。美國國際集團(American International Group Inc.)目前持有24,630股該公司股票，價值45.9萬美元，該公司在上個季度又購買了1,749股。最後，Group One Trading L.P.在第一季度增持了Crinetics PharmPharmticals的股票31.6%。Group One Trading L.P.現在持有該公司7318股股票，價值16.1萬美元，在上個季度又購買了1759股。對衝基金和其他機構投資者持有該公司94.42%的股票。

About Crinetics Pharmaceuticals

關於Crinetics製藥公司

(Get Rating)

(獲取評級)

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).

Crinetics製藥公司是一家臨牀階段製藥公司，專注於罕見內分泌疾病和內分泌相關腫瘤治療藥物的發現、開發和商業化。它的主要候選產品是Paltusotine，這是一種口服選擇性非肽生長抑素受體2型激動劑，已經完成了治療肢端肥大症的第三階段臨牀試驗，以及治療類癌綜合徵和無功能神經內分泌腫瘤(NETS)的第二階段臨牀試驗。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on Crinetics Pharmaceuticals (CRNX)
  • What Steelcase's Earnings Say About the Return to the Office?
  • The Institutions Hold On To Darden Restaurants International
  • These 3 Big Dividend Payers Also Boast Strong Price Growth
  • Is The Golden Age Of Homebuilding Already Over?
  • Natural Gas Prices Continue To Rally, These Stocks Should Benefit
  • 免費獲取StockNews.com的Crinetics PharmPharmticals研究報告(CRNX)
  • 斯蒂爾凱斯的收益説明瞭他重返辦公室的原因嗎？
  • 這些機構持有達頓餐飲國際公司的股份
  • 這三大股利支付者也擁有強勁的價格增長
  • 住房建設的黃金時代已經結束了嗎？
  • 天然氣價格繼續回升，這些股票應該會受益

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

獲得《Crinetics PharmPharmticals Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Crinetics製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論